EVO
Eaton Vance Ohio Municipal Income Trust

101
Mkt Cap
$1.06B
Volume
3,992.00
52W High
$5.37
52W Low
$2.84
PE Ratio
-6.02
EVO Fundamentals
Price
$2.99
Prev Close
$2.96
Open
$3.00
50D MA
$3.68
Beta
0.97
Avg. Volume
42,059.17
EPS (Annual)
-$0.5981
P/B
1.13
Rev/Employee
$178,593.71
Loading...
Loading...
News
all
press releases
What is HC Wainwright's Forecast for Evotec FY2025 Earnings?
Evotec AG (NASDAQ:EVO - Free Report) - Stock analysts at HC Wainwright decreased their FY2025 EPS estimates for shares of Evotec in a report released on Thursday, November 6th. HC Wainwright analyst...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Evotec (NASDAQ:EVO) Trading Down 8% - Here's What Happened
Evotec (NASDAQ:EVO) Shares Down 8% - Should You Sell...
MarketBeat·12d ago
News Placeholder
Equities Analysts Offer Predictions for Evotec Q3 Earnings
Evotec AG (NASDAQ:EVO - Free Report) - Investment analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Evotec in a research note issued to investors on Thursday...
MarketBeat·12d ago
News Placeholder
Evotec (NASDAQ:EVO) Shares Gap Down - Should You Sell?
Evotec (NASDAQ:EVO) Shares Gap Down - Here's Why...
MarketBeat·14d ago
News Placeholder
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Zacks·1mo ago
News Placeholder
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in...
PR Newswire·1y ago
News Placeholder
Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction
Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction PR...
PR Newswire·1y ago
News Placeholder
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused...
Business Wire·1y ago
News Placeholder
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS PR...
PR Newswire·2y ago
News Placeholder
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
CLARIS'S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC'S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIESAGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN...
Accesswire·2y ago

Latest EVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.